According to Ms. Ingrid Nota of the Department of Psychology, Health and Technology, University of Twente, Netherlands, "our PtDA can be a valuable aid in improving patient participation in medical decision-making about anti-rheumatic drugs. We developed this new tool in response to research among Dutch arthritis patients, which showed a need for quality improvement in information provision about treatments, and a patient desire to be more involved in decision-making."
Arthritis patients who were facing the decision to initiate a (different) DMARD were invited to participate in the study. In the first year, patients received a questionnaire four weeks after consulting the rheumatologist (control group, n=158). In the second year, patients were referred to use the PtDA and also received a questionnaire 4 weeks after consulting the rheumatologist (intervention group, n=123).
The PtDA was used by 57% of respondents in the intervention group. Users rated the PtDA as useful, easy to use and easy to understand. Of the patients who had used the tool, most stated that the PtDA contained new information (70%), that they learned a lot from it (71%), that it helped them to get insight into their preferences, worries, doubts and questions (70%), that it helped them discuss things with their rheumatologist (60%), and to make a decision about their medication (70%).
Compared to the control group, patients in the intervention group perceived a more active role in decision-making (p=0.01) and perceived the final choice to be more consistent with their personal values (p=0.02). No effects were found on satisfaction with the decision process, trust in physician, beliefs about medication, or adherence to medication. This project was financially supported by the Dutch Arthritis Association.
Video guides launched to help rheumati
|Contact: EULAR Press Office|
European League Against Rheumatism